Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong
Authors' conclusion
The findings of this retrospective cohort study of patients with type 2 diabetes in Hong Kong suggest that SGLT2I use was associated with a reduced risk of incident OAD and a lower rate of exacerbations in a clinical setting compared with DPP4I use. These findings further suggest that SGLT2Is may provide additional protective effects against OAD for patients with type 2 diabetes and that further investigation is warranted.
Study context
- Population
- Patients with T2D prescribed SGLT2Is or DPP4Is between January 1, 2015, and December 31, 2018, territory-wide electronic medical database, Hong Kong
- Participants
- 30,385 patients
- Exposure
- SGLT2i use vs DPP-4i use
- Outcome
- First incidence of obstructive airway disease (OAD) and count of OAD exacerbations
- Follow-up
- Median 2.2 years
Methodological detailsprevalent new-user design, propensity score matching
- Prevalent new-user design
- Propensity score matching
Main finding
As reported in the abstract
SGLT2Is vs DPP4IsEstimate (95% CI)P value
Incident OAD; matched non-OAD cohort: 5696 SGLT2Ivs 22 784 DPP4I users
HR 0.65(0.54–0.79)
P < 0.001OAD exacerbations; matched OAD cohort: 381 SGLT2Ivs 1524 DPP4I users
rate ratio 0.54(0.36–0.83)
P = 0.01Observational data: associations, not effects.
Further findings
- The associations were consistent in sex subgroup analysis
Original publication
Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong. JAMA Netw Open. Published 3 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →